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There is considerable variability in the devel-
opment of toxicity in response to lead expo-
sure in the general population. Genetic
factors that modify the absorption, metabo-
lism, or excretion of lead may inﬂuence lead
toxicity. Genetic variants that predispose
individuals to accumulation of lead could
occur in enzymes known to inﬂuence or regu-
late lead metabolism. For example, lead is
known to bind to the enzyme aminolevulinic
acid dehydratase (ALAD), and the absorption
of lead is inversely related to calcium stores
and dietary vitamin D intake (Chisolm et al.
1985; Mahaffey et al. 1986). Genetic variants
in the ALAD and vitamin D receptor genes
have been associated with lead exposure bio-
markers (Hu et al. 2001; Schwartz et al.
2000a, 2000b; Smith et al. 1995; Wetmur
et al. 1997).
Another potential candidate gene for sus-
ceptibility to lead exposure is the gene that is
altered in hemochromatosis (Onalaja and
Claudio 2000; Wright 1999). Hemochroma-
tosis is an autosomal recessive genetic disease
that produces an increase in the absorption of
ingested iron. Affected subjects may develop
iron overload, leading to diabetes, heart dis-
ease, and liver disease, but generally do not
present until mid- to late adulthood. A hemo-
chromatosis gene (HFE) variant (C282Y)
accounts for most cases (Feder et al. 1996). The
HFE variant H63D is also associated with
hemochromatosis but with a lower penetrance
(Waheed et al. 1997).
Both polymorphisms are very common in
the U.S. population. Approximately 7–17%
of the U.S. general population are heterozy-
gous for C282Y (Bradley et al. 1998; Cox
and Kelly 1998; Jouanolle et al. 1997; Phatak
et al. 1998), and the prevalence of the H63D
heterozygous genotype in the general popu-
lation has been estimated to be 10–32%
(Beutler 1997; Jouanolle et al. 1997). The
recent cloning of the HFE gene has made
available rapid screening tests using poly-
merase chain reaction (PCR) techniques to
identify subjects who carry either the C282Y
or the H63D allele (Burke et al. 1998;
Merryweather-Clarke et al. 1999). The high
combined prevalence of the two alleles sug-
gests that these two polymorphisms could
play a major role in the general population
in both the distribution of body iron and
the distribution of any metals that share
absorptive pathways with iron, such as lead.
Given the high prevalence of HFE variants
in the general population and the known asso-
ciation between iron absorption and lead
absorption, we hypothesized that these genetic
variants may be important modifiers of lead
toxicodynamics among heterozygotes. Previous
reports suggested that subjects with clinical
hemochromatosis had higher lead levels or
equivalent blood lead levels (Akesson et al.
2000; Barton et al. 1994). However, a pilot
study on 100 subjects we conducted for a
grant application showed a trend toward lower
blood lead levels among heterozygotes for
C282Y and H63D. We therefore left our
a priori hypothesis two tailed. To test this
hypothesis, we genotyped a population of
elderly men enrolled in an established cohort
study of lead biomarkers and chronic disease.
Materials and Methods
This study was conducted on a subsample of
the Normative Aging Study (NAS), a multi-
disciplinary longitudinal study of aging estab-
lished by the Veterans Administration in 1963
(Bell et al. 1972). Briefly, 2,280 men were
enrolled in the NAS. Participants received
their first medical examination between
1963 and 1968. Subsequently, subjects have
reported for medical examinations and stan-
dard blood and urine tests every 3–5 years.
During these visits, NAS participants ﬁll out
questionnaires on smoking history, education
level, food intake, and other risk factors that
may influence health. Beginning in 1991,
those who gave their informed consent pre-
sented to the Ambulatory Clinical Research
Center of Brigham and Women’s Hospital for
a K X-ray ﬂuorescence (KXRF) measurement
of lead content in the tibia and patella. Study
subjects were thus measured for bone lead
between 1991 and 1997. For this study, we
conducted a cross-sectional analysis using data
stemming from the most recent measurement
of bone lead for each subject.
Although each NAS subject had signed an
approved consent form signifying willingness
to have blood archived for unspeciﬁed future
testing, we were genotyping these archived
blood samples for carriers of a known genetic
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Because body iron burden is inversely associated with lead absorption, genes associated with
hemochromatosis may modify body lead burden. Our objective was to determine whether the
C282Y and/or H63D hemochromatosis gene (HFE) is associated with body lead burden. Patella and
tibia lead levels were measured by K X-ray ﬂuorescence in subjects from the Normative Aging Study.
DNA samples were genotyped for C282Y and H63D using polymerase chain reaction/restriction
fragment length polymorphism (PCR/RFLP). A series of multivariate linear regression models were
constructed with bone or blood lead as dependent variables; age, smoking, and education as indepen-
dent variables; and C282Y or H63D as independent risk factors and/or effect modiﬁers. Of 730 sub-
jects, 94 (13%) carried the C282Y variant and 183 (25%) carried the H63D variant. In the crude
analysis, mean tibia, patella, and blood lead levels were consistently lower in carriers of either HFE
variant compared with levels in subjects with wild-type genotypes. In multivariate analyses that
adjusted for age, smoking, and education, having an HFE variant allele was an independent predictor
of signiﬁcantly lower patella lead levels (p < 0.05). These data suggest that HFE variants have altered
kinetics of lead accumulation after exposure. Among elderly men, subjects with HFE variants had
lower patella lead levels. These effects may be mediated by alterations in lead toxicokinetics via iron
metabolic pathways regulated by the HFE gene product and body iron stores. Key words: aging,
hemochromatosis, lead, men, metals. Environ Health Perspect 112:746–750 (2004).
doi:10.1289/ehp.6581 available via http://dx.doi.org/ [Online 29 January 2004]
Environmental Medicine Articledisease. To maintain the conﬁdentiality of the
study subjects and to protect them from any
undue possible consequences with respect to
employment or health coverage, we created a
new data file for the cohort that was kept
anonymous and separate from the NAS master
data ﬁle. Data on potential confounders of the
association between HFE genotype and bone
lead levels were downloaded into this file, as
were the bone lead levels and genotype. All
identiﬁers were then deleted. These procedures
are consistent with those recommended by the
American Society of Human Genetics when
genotyping archived blood samples [American
Society of Human Genetics (ASHG) 1996;
Clayton et al. 1995]. The study and its
anonymization procedures were approved by
the Human Research Committee of Brigham
and Women’s Hospital.
Bone lead levels measured by KXRF. Bone
lead measurements were taken at two sites,
the mid-tibial shaft and the patella, with an
ABIOMED KXRF instrument (ABIOMED,
Inc., Danvers, MA, and the Harvard Metals
Epidemiology Research Group). The tibia
and patella have been targeted for bone lead
research because these two bones consist
mainly of pure cortical and trabecular bone.
A 30-min measurement was taken at the
mid-shaft of the left tibia and at the left
patella after each region had been washed
with a 50% solution of isopropyl alcohol.
The tibial midshaft was taken as the point
equidistant between the tibial plateau and the
medial malleolus. The KXRF beam collima-
tor was sited perpendicular to the flat bony
surface of the tibia and at the patella.
As a quality control measure, once a week
a 15-ppm phantom was positioned and meas-
ured 20 consecutive times overnight as a
ﬁrst-order calibration check. Analysis of means
and standard deviations was performed to dis-
close any signiﬁcant shift in accuracy or pre-
cision. Once each month, the entire set of
calibration phantoms (0, 5, 10, 15, 20, 30, 40,
50, and 100 ppm; true values checked by
inductively coupled plasma–mass spectrome-
try) was measured and a calibration curve was
calculated as a ﬁnal check on calibration.
Blood lead levels measured by graphite
atomic absorption spectrometry. Fresh blood
for lead measurement was taken in a special
lead-free tube containing Ethylenediamine-
tetraacetic acid (EDTA) and sent to ESA
Laboratories, Inc. (Chelmsford, MA). Blood
samples were analyzed by Zeeman back-
ground-corrected ﬂameless atomic absorption
spectrophotometer (graphite furnace). The
instrument was calibrated before use with
National Institute of Standard and Technology
materials. Ten percent of the samples were
run in duplicate, 10% were controls, and 10%
were blanks. In tests on reference samples
from the Centers for Disease Control and
Prevention, precision (percent relative standard
deviation) ranged from 8% for concentrations
< 30 µg/dL to 1% for higher concentrations.
Blood lead levels are measured at each triennial
NAS study visit. For this study, the blood lead
measurement most proximal to the bone lead
measurement in time was chosen.
Hemochromatosis genotyping. Puregene
DNA isolation kits (Gentra Systems, Inc.,
Minneapolis, MN) were used to extract the
DNA from the fresh blood sample. The
H63D variant was genotyped by PCR and
restriction fragment length polymorphism
(RFLP) analysis as previously described
(Cardoso et al. 1998). Brieﬂy, the DNA sam-
ple was ampliﬁed with two primers, 5´-ATG
GGT GCC TCA GAG CAG-3´ and 5’-AGT
CCA GAA GTC AAC AGT-3´, to generate a
210-bp fragment. The C282Y variant was
also genotyped by a separate PCR and RFLP
procedure (Cardoso et al. 1998). Wild-type
alleles are designated H, and variant alleles are
designated D. For C282Y, DNA sample was
amplified with two primers, 5´-TGG CAA
GGG TAA ACA GAT CC-3´ and antisense
primer 5´-TAC CTC CTC AGG CAC TCC
TC-3´ (Feder et al. 1996). A random sample
of 10% of subjects was run in duplicate as a
quality control measure. Genotypes were also
determined on control blood known to be
from subjects homozygous for the wild-type
genotype and heterozygous and homozygous
for each variant genotype. Wild-type alleles
are designated C, and variant alleles are desig-
nated Y. Joint genotypes are expressed using
both categories. For example, a subject wild-
type for both C282Y and H63D is designated
CC HH, and a subject heterozygous for both
variants is designated CY HD.
Data analysis. We conducted a cross-
sectional analysis of the association between
HFE variants and bone/blood lead concentra-
tion among elderly men. We first compared
characteristics of subjects who had all the data
of interest, including genotypes, bone/blood
lead levels, and covariate data with subjects who
were not included because of missing data.
Allele and genotype frequencies and tests for
Hardy-Weinberg equilibrium were performed.
Univariate distributions of continuous variables
were examined to determine departures from
normality. For quality control purposes, we
identiﬁed and omitted tibia and patella bone
lead measurements with estimated uncertainties
> 10 and 15 µg/g, respectively (these measure-
ments usually reflect excessive patient move-
ment during the measurement). Such
procedures are standard in analysis of bone lead
data (Hu 1998; Hu et al. 1991). Because we
did not make an a priori assumption that either
cortical or trabecular bone lead is of greater sig-
niﬁcance with respect to HFE variants, analyses
were repeated for the summary measures of
both tibia and patella lead.
The distributions of demographic and
lifestyle characteristics and bone/blood lead
levels by genotype (wild-type vs. C282Y
or H63D carrier) were examined, and differ-
ences were tested by chi-square or Student’s
t-test as appropriate. Multivariate linear regres-
sion was used to model determinants of tibia
lead, patella lead, and blood lead. To simplify
the analysis, we decided a priori to combine the
data on the two alleles into a single indicator
term (i.e., presence of one or two copies of
either gene variant) if the bivariate analysis of
genotype and bone/blood lead levels demon-
strated consistent ﬁndings for both C282Y and
H63D. Major core model determinants, based
on the previous work of this laboratory,
include age, education level, and cumulative
smoking (Hu 1998; Hu et al. 1996). Each of
these regressions was repeated, adding an indi-
cator variable for hemochromatosis genotype.
To assess whether the genotype may serve as an
effect modiﬁer of the relationship between our
covariates and our lead biomarkers, we also
compared the β-estimates of core-model deter-
minants in regressions of our lead biomarkers
stratiﬁed by genotype (C282Y or H63D carrier
vs. wild-type). If a core model β-estimate was
different between genotypes [i.e., the HFE vari-
ant model β-estimate was outside the 95% con-
ﬁdence interval (CI) bounds of the wild-type
model], an additional exploratory regression
model was run that included a cross-product
term for interaction between genotype and the
core-model determinant of interest.
In models using blood lead as the depen-
dent variable, patella or tibia lead levels have
been included as independent variables because
they are major predictors of blood lead levels in
the NAS, probably because bone stores are
the major source of lead exposure among
this cohort of elderly men (Hu et al. 1998).
However, if HFE variants predict changes in
bone lead levels, then these bone lead levels
may be an intermediate variable between
changes in blood lead associated with HFE
variants. Therefore, we did not include bone
lead levels as a covariate in models to predict
blood lead levels.
In the ﬁnal models, we combined the two
genotypes into a single indicator variable rep-
resenting gene variant presence or dose. In
one model, the presence of either variant was
coded as yes/no. In the other model, we
examined the dose effect of the variants by
coding the genotype on an ordinal scale
(none, one, or two variants present).
Results
A total of 765 subjects in the NAS participated
in the KXRF study and had archived blood. Of
these, 730 were genotyped for H63D and
C282Y. Archived blood from 35 subjects
could not be reliably genotyped. The means
and distributions of blood lead, bone lead, age,
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and the 35 who were not genotyped were simi-
lar (data not shown). The overall prevalence
values for C282Y genotypes were wild-type,
87.1%; heterozygote, 12.2%; and homozygote,
0.7%. The prevalence values of the H63D
genotypes were wild-type, 74.9%; heterozy-
gote, 22.6%; and homozygote, 2.5%. The
distributions of both genotypes conformed to
Hardy-Weinberg expected frequencies
(C282Y: chi square = 0.93, p = 0.34; H63D:
chi square = 1.69, p = 0.19). When collapsed
into a single variable indicating the presence
or absence of either variable, 261 (36.0%) of
subjects in this sample carried at least one
copy of either HFE variant.
Table 1 shows the distribution of the lead
biomarkers and covariates stratiﬁed by geno-
type. The overall trend in the bone and blood
lead levels was that carriers of HFE variants
had lower bone and blood lead levels. Subjects
with either one or two copies of either allele
had lower bone or blood lead levels on average
than did wild-type subjects (Table 1). As in
previous studies, smoking, age, and education
levels were important predictors of bone and
blood lead concentration in the core regression
models (Table 2).
In the multivariate regression models
using either H63D or C282Y separately, lead
biomarkers were consistently lower among
subjects carrying at least one copy of either
the C282Y or H63D allele (Table 3). Given
these results, we collapsed the two variants
into a single dichotomous variable indicating
the presence or absence or either variant, and
a three-level categorical variable indicating the
dose of either variant (none, one, or two alle-
les) of either C282Y or H63D. Subjects with
at least one HFE variant had significantly
lower patella and blood lead levels than did
subjects with wild-type genotypes (Table 3).
Similar to the results of the crude analysis,
subjects with HFE variants consistently had
lower bone and blood levels than did subjects
with wild-type alleles in all multivariate mod-
els (Table 3). To explore for effect modiﬁca-
tion, we then repeated the linear regression
models stratifying on the presence or absence
of an HFE variant. In the stratiﬁed model, the
coefficients for age, smoking, and education
differed between models of wild-type carriers
and HFE variant carriers, whereas only the
interaction term for age*HFE (coded as carrier
of either C282Y or H63D) in the model for
tibia lead levels reached statistical signiﬁcance
(β = –0.3; 95% CI, –0.6 to –0.01; p < 0.05).
The interaction is in the direction of a
decreased age–bone lead slope among the HFE
variant carriers compared with wild-type indi-
viduals. To better illustrate this interaction, we
created smoothed plots of tibia lead versus age,
stratified by HFE variant carrier status and
adjusted for smoking and education. Figure 1
illustrates this interaction. To construct this
ﬁgure, we repeated the stratiﬁed models using
the residuals of age regressed by smoking and
education as the independent variable. The
residuals of tibia lead levels regressed by smok-
ing and education were used as the dependent
variable. The residuals were then plotted, and
the smoothed plot was constructed using a
lowess smoothing function with a bandwidth
of 0.3. There was also evidence of modiﬁcation
by HFE genotype on the association between
patella and blood lead levels. The β-coefﬁcient
for blood lead in predicting patella lead among
wild-type genotype subjects was 0.08 (95% CI,
0.06 to 0.09), whereas among HFE variant car-
riers it was 0.05 (95% CI, 0.03 to 0.07). The
interaction term for this difference was (–0.03;
p = 0.041). We also constructed a smoothed
plot of patella lead versus blood lead levels
stratiﬁed by presence or absence of either HFE
variant (Figure 2). The association between
patella and blood lead levels is nearly linear
among wild-type subjects but is nonlinear
among HFE variants carriers, in which there
appears to be a relatively flat association
between patella lead and blood lead levels at
low and high blood lead levels.
Discussion
Our results indicate that among elderly men,
the presence of a hemochromatosis variant
allele (C282Y or H63D) predicts lower bone
and blood lead concentrations. Because iron
status is inversely associated with lead absorp-
tion, we believe that these results may be sec-
ondary to increased iron stores among HFE
variant carriers causing decreased lead absorp-
tion in the gastrointestinal tract. During iron
deﬁciency, regulatory mechanisms that cause an
increase in iron absorption cause an increase in
the percentage of ingested lead that is absorbed
(Barton et al. 1978; Mahaffey-Six and Goyer
1972). Several clinical studies also have sup-
ported this association. An inverse association
between dietary iron and blood lead level was
found by Bradman et al. (2001) and Hammad
et al. (1996) in separate studies. Similarly, our
research group found an association between
biomarkers of iron deficiency and elevated
blood lead levels in children (Wright et al.
Environmental Medicine | Wright et al.
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Table 3. Independent associations of HFE variants in multiple linear regression models (95% CI).
HFE Variant Patella Pb Tibia Pb Blood Pb
Allele-speciﬁc effects
C282Y –4.5 (–9.3 to 0.4)** –2.5 (–6.0 to 1.0) –0.3 (–1.0 to 0.5)
H63D –3.6 (–7.1 to –0.007)* –1.9 (–4.5 to 0.7) –0.6 (–1.1 to –0.1)*
Combined allele effectsa
Presence of either HFE variant –3.5 (–6.6 to –0.5)* –1.8 (–4.1 to 0.5) –0.4 (–0.9 to 0.04)**
Allele dose effectsb
One HFE variant –3.3 (–6.5 to –0.004)* –1.3 (–3.7 to 1.1) –0.3 (–0.8 to 0.2)
Two HFE variants –5.2 (–11.7 to 1.5) –4.6 (–9.5 to 0.3)** –1.1 (–2.1 to 0.009)**
The referent group for all HFE variables consists of subjects who are wild-type for both C282Y and H63D (CC HH). All mod-
els include age, education level, and smoking.
aVariable coded as presence of one or two C282Y or H63D variants. bVariable coded as none, one, or two copies of either
C282Y or H63D. *p < 0.05. **p < 0.10.
Table 1. Comparison of the distribution [mean ± SD or no. (%)] of covariates and lead biomarkers across
genotypes of HFE variants (n = 730).
Genotype CC HH CY HH YY HH CY HD CC HD CC DD
No. (%) 469 (64) 73 (10) 5 (1) 16 (2) 149 (20) 18 (3)
Age (years) 70.7 (7.3) 70.5 (7.4) 73.1 (3.6) 68.0 (7.5) 71.5 (7.0) 70.2 (7.5)
Education (% ≤ high school) 46 38 80 50 46 61
Smoking (pack years) 22.6 (25.3) 24.7 (31.0) 7.6 (12.4) 20.4 (23.2) 21.7 (26.4) 22.0 (22.9)
Patella lead (µg/g) 31.7 (23.1) 25.5 (17.2)** 30 (30.5) 19.9 (7.4)** 28.7 (18.5) 29.9 (14.5)
Tibia lead (µg/g) 23.4 (16.7) 19.5 (12.9)** 28.8 (19.0) 14.6 (7.2)** 22.3 (12.8) 18.6 (11.7)
Blood lead (µg/dL) 5.1 (3.4) 5.0 (3.2) 4.8 (1.9) 4.1 (1.7)** 4.6 (2.5)* 3.8 (2.5)
Abbreviations: CC, wild-type C282Y; CY, heterozygote C282Y; DD, homozygote H63D; HD, heterozygote H63D; HH, wild-type
H63D; YY, homozygote C282Y.
*p < 0.10 compared with CC HH (Student’s t-test). **p < 0.05 compared with CC HH (Student’s t-test).
Table 2. Core linear regression models of bone and blood lead levels.
Blood lead Patella lead Tibia lead
Age (years) 0.02 (–0.01 to 0.05) 0.8 (0.6 to 1.0)* 0.7 (0.6 to 0.9)*
Education
Referent group: college graduate — — —
Tech school/some college –0.2 (–0.8 to 0.5) 4.1 (0.1 to 8.2)* 3.5 (0.5 to 6.5)*
High school graduate 0.5 (–0.1 to 1.1) 10.0 (6.2 to 13.7)* 8.0 (5.2 to 10.7)*
High school dropout or grade school 1.0 (0.2 to 1.9)* 14.6 (9.1 to 20.0)* 14.1 (10.2 to 18.1)*
Smoking (pack years) 0.02 (0.01 to 0.03)* 0.1 (0.1 to 0.2)* 0.05 (0.004 to 0.09)*
Results are β-coefﬁcients (95% CIs) for independent variables in predicting lead exposure biomarkers. Independent variables
included as covariates in all models were age, education, and smoking.
*p < 0.05.1999). Other clinical studies have demon-
strated that high body iron stores are associated
with decreased blood lead levels (Graziano
et al. 1990). These previous studies formed the
basis of our hypothesis that the HFE gene
would be a candidate gene for modifying lead
absorption and body burden.
Our results confirm that HFE genotype
does indeed predict differences in lead bio-
markers, although our results differ from those
of previous studies in terms of the direction of
the effect. Both previous reports (Akesson
et al. 2000; Barton et al. 1994) suggested that
subjects with hemochromatosis had higher
blood lead levels. Our study differs from the
previous reports in being a cohort-based study,
in focusing mainly on subjects heterozygous
for HFE variants, in being conducted exclu-
sively in men, and in the older average age of
the participants. All these factors may play a
role in explaining the different results. In both
previous reports, investigators compared sub-
jects with hemochromatosis (i.e., homozygotes
or compound heterozygotes) with control
groups. In the earliest report, Barton et al.
(1994) hypothesized that if iron deficiency
and lead absorption were associated, lead
absorption would be increased in subjects with
hemochromatosis. In the study by Barton et al.
(1994), blood lead levels were higher among
subjects with clinical hemochromatosis than
among controls. The mean blood lead level
among 44 subjects with clinical hemo-
chromatosis was 5.6 µg/dL and among 33 con-
trols was 3.6 µg/dL (p < 0.05). In contrast,
Akesson et al. (2000) found no difference in
blood lead levels between hemochromatosis
subjects and controls. Instead, the investigators
found an association between higher blood lead
levels and longer duration of phlebotomy treat-
ment. Phlebotomy is the treatment for clinical
hemochromatosis. In attempting to explain this
ﬁnding, the authors speculated that lower iron
stores in phlebotomized subjects with
hemochromatosis caused an up-regulation of
the absorptive pathways by which iron and lead
are absorbed, thus increasing blood lead levels.
Because there are no physiologic mecha-
nisms for iron excretion, one possible explana-
tion for the different results of the three studies
is that age may serve as a proxy measure of
increasing body iron stores, which in turn is
inversely associated with lead absorption.
Under this hypothesis, the interaction between
tibia lead and age might reflect the down-
regulation of both iron and lead absorption as
body iron stores increase with age, a hypothesis
also proposed by Akesson et al. (2000). Older
subjects would, on average, have larger body
iron stores and as they advance in age would
absorb less environmental iron and less envi-
ronmental lead. This decrease in absorbed lead
with advancing age may cause the decrease in
both bone and blood lead seen in the older
subjects of the NAS cohort. HFE variant carri-
ers may have higher iron stores earlier in life
and may down-regulate iron and lead absorp-
tion sooner than subjects with wild-type geno-
types. The study by Akesson et al. (2000) also
suggests that body iron stores may regulate
iron/lead absorption in subjects with clinical
hemochromatosis. Subjects heterozygous for
C282Y have evidence of higher body iron
stores than do subjects with wild-type geno-
types (Datz et al. 1998; Garry et al. 1997),
and body iron stores still regulate iron absorp-
tion inversely even in subjects with clinical
hemochromatosis (McLaren et al. 1991).
Therefore, subjects with HFE variants may
have higher iron stores on average and lower
lead absorption, because of the decreased risk
of iron deﬁciency. Of interest, the mean age in
our study was 70.8 years, whereas in the Barton
et al. (1994) and Akesson et al. (2000) studies,
Environmental Medicine | Hemochromatosis and lead
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Figure 2. Lowess smoothed plot of residuals for patella lead levels versus blood lead levels. Wild-type subjects (A) have the genotype CC HH. HFE variant carriers (B)
have at least one copy of C282Y or H63D.
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Figure 1. Smoothed plot of residuals for tibia lead levels versus age. (A) Relationship among wild-type subjects (CC HH). (B) Same relationship among subjects
with at least one copy of C282Y or H63D. Values were adjusted for education level and smoking.Environmental Medicine | Wright et al.
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the mean ages were 49.4 years and 55.5 years,
respectively. Higher lead levels among subjects
with hemochromatosis were noted only in
the Barton et al. (1994) study, which had the
youngest participants. Our study population
may have been particularly predisposed to ele-
vated iron stores because it was conducted
solely in men, a group that may have a particu-
larly low risk of iron deﬁciency. A similar study
in a population at high risk for iron deﬁciency,
such as women of child-bearing age, may be
expected to have different results. We would
note that in Barton et al. (1994), female sub-
jects with hemochromatosis had higher blood
lead levels than did male hemochromatosis sub-
jects, whereas control female patients had lower
blood lead levels than did male controls.
There are limitations to this study. We
have no data on female subjects and can only
speculate on sex-speciﬁc effects of HFE variants
on lead dose biomarkers. There is also the pos-
sibility that population substructure may have
produced our results. Such an effect is less
likely given the homogenous ethnicity of the
NAS cohort. More than 95% of subjects are
Caucasian. There are no known differences in
risk for lead exposure within subgroups of
men with European ancestry. We believe that
population substructure is therefore an unlikely
explanation for our ﬁndings.
In summary, in a cohort study of elderly
men, HFE variants predicted lower patella
and blood lead levels. HFE variants also
modiﬁed the effect of age on tibia lead levels,
with younger subjects carrying HFE variants
having higher tibia lead levels and older sub-
jects with HFE variants having lower tibia
lead levels. These results may be caused by
the effect of the HFE gene product on
increasing body iron stores with the eventual
down-regulation of lead absorption.
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